Compare AbbVie Inc (ABBV) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

HLAL trades at $71.16, up 1.22% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $71-$73, with support at $70 and $69. Recent dividend activity includes a $0.02 distribution scheduled for June 2026, though key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity.

The outlook remains cautious due to weak technical momentum and lack of recent financial data. Risks include market volatility and potential earnings uncertainty, while opportunities hinge on future corporate updates. Investors should await fresh earnings reports for a clearer valuation picture amid current bearish signals.